10491 results for 'make nik'

Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus eryth

When PhDs and Post-Docs start in new lab they have the best intentions to keep their lab books up to date with notes, new research methods, data, and protocol information. These best efforts us

What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W

Endocrinology · ImmunologyCortisol and the Immune ResponseCortisol is the body’s primary stress hormone — a glucocorticoid released by the adrenal gland that powerfully shapes the immune system. Actin

Ralitsa R. Madsen – University of Cambridge Metabolic Research Laboratories Each one of us is the result of an extraordinary developmental proces

Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like

Apoptosis is not one pathway but three routes into the same execution machinery. A death ligand at the surface, a mitochondrion that loses outer-membrane integrity, and a granzyme delivered by a cyto

Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi

Imagine a highly trained soldier, elite and effective, sent to the front lines of a relentless war. Day after day, they fight without rest, their supplies dwindle, and the enemy never stops coming. Ev

In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regu

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does

Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin

Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D

PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are

Introduction Transformation of bacteria with plasmids is not only of note for bacterial studies but also can be used for gene expression studies in mammalian cells. Most plasmids are of bact

Antibodies · Reagent GuideMonoclonal vs Polyclonal Antibodies: Key DifferencesMonoclonal and polyclonal antibodies are the two workhorse reagent types in research, diagnostics and therapy. Monoclonals

Metabolism · Biochemistry Guide 10 Steps of Glycolysis: Enzymes, Diagram & ATP Yield The complete ten-step pathway that converts one glucose m

Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40